Jacqualyn A. Fouse
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Madrigal Publishes MAESTRO-NASH Secondary Analysis Data. Madrigal Pharmaceuticals has published data from a pre-specified secondary analysis of its Phase 3 MAESTRO-NASH study in the Journal of Hepatology. The analysis evaluates how patients with altered MASH profiles respond to Rezdiffra. This update provides additional clinical context for the drug's performance in specific patient groups.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Incyte receives mixed analyst updates with price target changes. Incyte saw two recent analyst actions with differing views. Truist Securities raised its price target to $115 while maintaining a Hold rating. Conversely, HC Wainwright reiterated a Buy rating and kept its target at $152. These moves reflect a wide range of expectations among analysts for the stock's future performance.
Transaction History
| AGIO | ▲ Buy | Option Exercise | 2,816 | $0 | 6/18/2026 | View on chart |
| MDGL | ▲ Buy | Grant | 454 | $0 | 6/17/2026 | View on chart |
| INCY | ▲ Buy | Grant | 1,642 | $0 | 6/8/2026 | View on chart |
| MDGL | ▲ Buy | Grant | 203 | $0 | 6/20/2025 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 2,120 | $0 | 6/20/2025 | View on chart |
| INCY | ▲ Buy | Grant | 2,518 | $0 | 6/10/2025 | View on chart |
| AGIO | ▼ Sell | Open Market | 7,497 | $194K | 4/10/2025 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 15,933 | $0 | 4/8/2025 | View on chart |
| MDGL | ▲ Buy | Grant | 894 | $0 | 3/10/2025 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 3,388 | $0 | 6/13/2024 | View on chart |
| INCY | ▲ Buy | Grant | 2,830 | $0 | 6/12/2024 | View on chart |
| AGIO | ▼ Sell | Open Market | 7,791 | $215K | 4/10/2024 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 15,934 | $0 | 4/8/2024 | View on chart |
| AGIO | ▼ Sell | Open Market | 10,722 | $232K | 1/24/2024 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 23,900 | $0 | 1/20/2024 | View on chart |
| AGIO | ▼ Sell | Open Market | 8,391 | $193K | 1/9/2024 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 17,500 | $0 | 1/5/2024 | View on chart |
| AGIO | ▼ Sell | Open Market | 10,718 | $304K | 6/30/2023 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 23,900 | $0 | 6/28/2023 | View on chart |
| INCY | ▲ Buy | Grant | 2,505 | $0 | 6/14/2023 | View on chart |
| AGIO | ▼ Sell | Tax Withholding | 4,731 | $101K | 4/12/2023 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 15,933 | $0 | 4/8/2023 | View on chart |
| AGIO | ▼ Sell | Tax Withholding | 3,648 | $105K | 2/16/2023 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 11,333 | $0 | 2/14/2023 | View on chart |
| INCY | ▲ Buy | Grant | 252 | $20K | 12/30/2022 | View on chart |
| INCY | ▲ Buy | Grant | 291 | $19K | 9/30/2022 | View on chart |
| INCY | ▲ Buy | Grant | 275 | $21K | 6/30/2022 | View on chart |
| INCY | ▲ Buy | Grant | 2,144 | $0 | 6/15/2022 | View on chart |
| INCY | ▲ Buy | Grant | 280 | $22K | 3/31/2022 | View on chart |
| AGIO | ▼ Sell | Tax Withholding | 3,674 | $107K | 2/22/2022 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 12,379 | $0 | 2/18/2022 | View on chart |
| AGIO | ▼ Sell | Tax Withholding | 3,505 | $107K | 2/14/2022 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 11,334 | $0 | 2/14/2022 | View on chart |
| INCY | ▲ Buy | Grant | 289 | $21K | 12/31/2021 | View on chart |
| INCY | ▲ Buy | Grant | 271 | $19K | 9/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
AGIO Valuation Concerns Ahead of Q3 2026 Call
AGIO’s November earnings call sparked debate that the shares might be undervalued by about 28%, while analysts noted the stock appears fully priced against current sales. The company will host its third‑quarter 2026 results call on Nov. 5, which could clarify expectations. After a 29% decline over three months, Truist Securities lowered its target price to $37, reflecting a more cautious view.
AGIO Valuation Concerns Ahead of Q3 2026 Call. AGIO’s November earnings call sparked debate that the shares might be undervalued by about 28%, while analysts noted the stock appears fully priced against current sales. The company will host its third‑quarter 2026 results call on Nov. 5, which could clarify expectations. After a 29% decline over three months, Truist Securities lowered its target price to $37, reflecting a more cautious view.